Galux, an AI-powered antibody drug design company, has closed a $28.8 million (42 billion KRW) Series B funding round, bringing its total funding to $46.6 million (68 billion KRW).

The Series B round was led by Yuanta Investment, with participation from Korea Development Bank, Intervest, DAYLI Partners–NH Investment & Securities consortium, Pathway Investment, SL Investment, Ncore Ventures–TKG Ventures consortium, Sneakpeek Investment, KOREA INVESTMENT & SECURITIES, and Mirae Asset Securities. Notably, Intervest has been supporting Galux since its seed stage and continued with follow-on investments, while DAYLI Partners and Pathway Investment also participated in both Series A and B rounds, reaffirming their confidence in the company’s technology and long-term growth potential.

“AI drug discovery and protein drug design are fields where competitive advantages are difficult to build in a short period,” said Kim Sang-gyun, Managing Director at Intervest. “Galux demonstrated exceptional technical depth from the seed stage, backed by years of accumulated research experience. We’ve witnessed their continuous advancement in research outcomes and technical sophistication, which led us to invest consecutively through Series A and B.”

Galux’s protein design AI technology is recognized as world-class, particularly in the de novo antibody design field, where the company is considered among the global leaders. De novo antibody design involves creating entirely new amino acid sequences and structures to achieve desired functions—an extremely challenging area with limited success cases worldwide.

The company has recently achieved breakthrough results by securing high-affinity antibodies through small-scale designs, demonstrating success rates hundreds of times higher than conventional methods. Built on experimental and research infrastructure capable of rapidly validating AI-designed drug candidates, Galux continues to enhance the precision and maturity of its drug design AI platform.

On the business front, the company is expanding partnerships both domestically and internationally. Galux has formalized its global expansion through a joint research agreement with Boehringer Ingelheim and is collaborating on drug development with leading Korean companies including Celltrion, LG Chem, Hanall Biopharma, and Y-Biologics.

The Series B proceeds will be strategically allocated to core R&D areas including AI platform technology advancement, R&D infrastructure expansion, talent acquisition, and preclinical validation of drug candidates. Through these investments, Galux plans to further strengthen its technological competitiveness, achieve tangible drug development results in challenging drug targets previously inaccessible through conventional methods, pioneer new markets, and reinforce its global competitiveness.

“Protein drug design technology is rapidly gaining importance across the entire drug development landscape,” said Cha-ok Seok, CEO of Galux. “Within this field, Galux is demonstrating top-tier capabilities in de novo antibody design, the most challenging area. With this investment, we will accelerate platform advancement and pipeline validation to deliver meaningful business results in the global market and contribute to the development of more effective therapies.”